Reza Soleimani
Research Subjects
Research Interests
Reza Soleimani has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hector Rodriguez-Villalobos
Department of Clinical Microbiology, Cliniques universitaires Saint-Luc, Brussels, Belgium
4 shared publications - Benoît Kabamba-Mukadi
Department of Microbiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3 shared publications Catherine Fillée
Department of Clinical Biochemistry, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium
2 shared publicationsDamien Gruson
Department of Laboratory Medicine Cliniques Universitaires Saint‐Luc Brussels Belgium
2 shared publications- Damien Gruson
Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium
2 shared publications Julien Favresse
Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium
2 shared publications
Latest Publications
- Open Access
- 4 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6627
Molecular Diagnostics for Group A Streptococcal Pharyngitis: Clinical and Economic Benefits in the Belgian Healthcare Context
(1) Background: Group A Streptococcal (GAS) pharyngitis is common, resulting in numerous ambulatory visits. Accurate diagnosis is challenging. This study evaluated the clinical utility, cost, and performance of a nucleic acid amplification test (NAAT) for GAS detection, comparing it to a rapid antigen detection test (RADT) and throat culture. Additionally, we assessed the diagnostic stewardship related to these testing methods to ensure appropriate antibiotic use in clinical practice. Methods: Between November 2022 and February 2023, 82 throat swabs were analyzed, with McIsaac clinical scores calculated for each. The Abbott ID NOW STREP A 2 NAAT and Sekisui Diagnostics’ OSOM® STREP A RADT were performed, followed by bacterial culture. Diagnostic performance was compared using culture as the gold standard. Results: Of the 82 samples, 28 (34.14%) tested positive for pathogenic germs, primarily Streptococcus pyogenes (92.85%). RADTs showed a sensitivity of 80.76% and a specificity of 100%, while NAATs demonstrated a sensitivity of 100% and specificity of 96.42%. Cost analysis indicated the need for reimbursement adjustments to optimize NAAT’s economic benefits. Clinical data indicated that symptoms alone were insufficient for reliable diagnosis. Conclusions: This study confirmed the superior sensitivity of Abbott’s Strep A2 NAAT over RADT. Given the Belgian guidelines against routine antibiotic treatment for pharyngitis and considering local treatment recommendations and cost, implementing NAAT for GAS detection in Belgian laboratories is less beneficial. However, the role of NAAT in supporting antimicrobial stewardship by ensuring appropriate antibiotic use remains significant.
- 4 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6627
Open AccessMolecular Diagnostics for Group A Streptococcal Pharyngitis: Clinical and Economic Benefits in the Belgian Healthcare Context
(1) Background: Group A Streptococcal (GAS) pharyngitis is common, resulting in numerous ambulatory visits. Accurate diagnosis is challenging. This study evaluated the clinical utility, cost, and performance of a nucleic acid amplification test (NAAT) for GAS detection, comparing it to a rapid antigen detection test (RADT) and throat culture. Additionally, we assessed the diagnostic stewardship related to these testing methods to ensure appropriate antibiotic use in clinical practice. Methods: Between November 2022 and February 2023, 82 throat swabs were analyzed, with McIsaac clinical scores calculated for each. The Abbott ID NOW STREP A 2 NAAT and Sekisui Diagnostics’ OSOM® STREP A RADT were performed, followed by bacterial culture. Diagnostic performance was compared using culture as the gold standard. Results: Of the 82 samples, 28 (34.14%) tested positive for pathogenic germs, primarily Streptococcus pyogenes (92.85%). RADTs showed a sensitivity of 80.76% and a specificity of 100%, while NAATs demonstrated a sensitivity of 100% and specificity of 96.42%. Cost analysis indicated the need for reimbursement adjustments to optimize NAAT’s economic benefits. Clinical data indicated that symptoms alone were insufficient for reliable diagnosis. Conclusions: This study confirmed the superior sensitivity of Abbott’s Strep A2 NAAT over RADT. Given the Belgian guidelines against routine antibiotic treatment for pharyngitis and considering local treatment recommendations and cost, implementing NAAT for GAS detection in Belgian laboratories is less beneficial. However, the role of NAAT in supporting antimicrobial stewardship by ensuring appropriate antibiotic use remains significant.
- Open Access
- 17 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S278-S283
SLC14A1 gene sequencing shows the JK*01W.06 allele in a JK1 patient with an anti-JK1
- 17 December 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S278-S283
Open AccessSLC14A1 gene sequencing shows the JK*01W.06 allele in a JK1 patient with an anti-JK1
- Open Access
- 10 January 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 125-129
Multicentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains
- 10 January 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 28, 125-129
Open AccessMulticentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 292, 114129
Usefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays
- 1 June 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 292, 114129
Open AccessUsefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays
- Open Access
- 19 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5655-5659
Rapid COVID‐19 antigenic tests: Usefulness of a modified method for diagnosis
The current reliable recommended test for coronavirus disease 2019 (COVID‐19) diagnosis is quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR). Rapid antigen test devices could be useful as they are less expensive, faster without the need of specialized laboratories to perform the test. We report the performances of two rapid immunochromatographic antigen testing devices compared with RT‐qPCR for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal samples. We carried out a lateral‐flow tests study on 401 nasopharyngeal swab samples from nonduplicated suspected COVID‐19 subjects. An equal volume of universal transport medium tubes‐containing samples (dilution ratio = 1:15) were added to the manufacturer's extraction buffer solution (dilution ratio = 1:2) and analyzed on BioSpeedia COVID19Speed‐Antigen Test and on Abbott Panbio™ COVID‐19 Ag Rapid Test, devices. Qualitative results were compared to those obtained by the RT‐qPCR (Allplex™ SARS‐CoV‐2 Assay Seegene). Based on our data, the overall sensitivity for BioSpeedia and Panbio devices was estimated at 65.5% and 75.0%, respectively. The sensitivity was greater for cycle threshold values less than 25 achieving 90.4 and 96.8 for BioSpeedia and Panbio devices, respectively. A perfect specificity of 100.0% was observed for both devices.
- 19 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5655-5659
Open AccessRapid COVID‐19 antigenic tests: Usefulness of a modified method for diagnosis
The current reliable recommended test for coronavirus disease 2019 (COVID‐19) diagnosis is quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR). Rapid antigen test devices could be useful as they are less expensive, faster without the need of specialized laboratories to perform the test. We report the performances of two rapid immunochromatographic antigen testing devices compared with RT‐qPCR for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal samples. We carried out a lateral‐flow tests study on 401 nasopharyngeal swab samples from nonduplicated suspected COVID‐19 subjects. An equal volume of universal transport medium tubes‐containing samples (dilution ratio = 1:15) were added to the manufacturer's extraction buffer solution (dilution ratio = 1:2) and analyzed on BioSpeedia COVID19Speed‐Antigen Test and on Abbott Panbio™ COVID‐19 Ag Rapid Test, devices. Qualitative results were compared to those obtained by the RT‐qPCR (Allplex™ SARS‐CoV‐2 Assay Seegene). Based on our data, the overall sensitivity for BioSpeedia and Panbio devices was estimated at 65.5% and 75.0%, respectively. The sensitivity was greater for cycle threshold values less than 25 achieving 90.4 and 96.8 for BioSpeedia and Panbio devices, respectively. A perfect specificity of 100.0% was observed for both devices.
- Open Access
- 14 August 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (3) , 1465-1477
Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID‐19 patients
Background Since December 2019 we have been in the battlefield with a new threat to the humanity, known as SARS‐CoV‐2, which causes COVID‐19, characterized by viral pneumonia. It may be asymptomatic or cause various symptoms, ranging from flu like symptoms to ARDS and eventually death. At present, the only reliable test for COVID‐19 diagnosis is RT‐qPCR. Assessing the immune response against SARS‐CoV‐2 could increase the detection sensitivity of infected population. Hereby, we report the performances of a fully automated chemiluminescent immunoassay (CLIA) on 276 serum samples. Methods One hundred samples obtained from COVID‐19 negative subjects (COVID‐19 free) were analyzed to evaluate diagnostic specificity of antibody (Ab) detection. Thereafter, 176 samples obtained from 125 patients with confirmed COVID‐19 (COVID‐19 patients) were selected to assess the diagnostic sensitivity of the CLIA. All samples were analyzed on MAGLUMITM 800 platform. Results All COVID‐19 free samples had Ab levels below the cut‐off values. Hence, the diagnostic specificity was estimated at 100% (95%CI= 96.3‐100.0; PPV= 100%). By the 18th day from the onset of symptoms we reached to an optimal diagnostic sensitivity (more than 95.0 %) In fact, the diagnostic sensitivity increased over time and between 15 to 25 days after symptoms onset, reached to 95.5% (95% CI= 84.9‐99.2). Conclusion The new automated CLIA analyzer appeared to be a robust and reliable method to measure specific Ab against COVID‐19 at a high throughput. Our data suggest that combining Ab and nucleic acid detection could increase the diagnostic sensitivity.
- 14 August 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (3) , 1465-1477
Open AccessClinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID‐19 patients
Background Since December 2019 we have been in the battlefield with a new threat to the humanity, known as SARS‐CoV‐2, which causes COVID‐19, characterized by viral pneumonia. It may be asymptomatic or cause various symptoms, ranging from flu like symptoms to ARDS and eventually death. At present, the only reliable test for COVID‐19 diagnosis is RT‐qPCR. Assessing the immune response against SARS‐CoV‐2 could increase the detection sensitivity of infected population. Hereby, we report the performances of a fully automated chemiluminescent immunoassay (CLIA) on 276 serum samples. Methods One hundred samples obtained from COVID‐19 negative subjects (COVID‐19 free) were analyzed to evaluate diagnostic specificity of antibody (Ab) detection. Thereafter, 176 samples obtained from 125 patients with confirmed COVID‐19 (COVID‐19 patients) were selected to assess the diagnostic sensitivity of the CLIA. All samples were analyzed on MAGLUMITM 800 platform. Results All COVID‐19 free samples had Ab levels below the cut‐off values. Hence, the diagnostic specificity was estimated at 100% (95%CI= 96.3‐100.0; PPV= 100%). By the 18th day from the onset of symptoms we reached to an optimal diagnostic sensitivity (more than 95.0 %) In fact, the diagnostic sensitivity increased over time and between 15 to 25 days after symptoms onset, reached to 95.5% (95% CI= 84.9‐99.2). Conclusion The new automated CLIA analyzer appeared to be a robust and reliable method to measure specific Ab against COVID‐19 at a high throughput. Our data suggest that combining Ab and nucleic acid detection could increase the diagnostic sensitivity.
- 22 April 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (12) , 2037-2045
Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing
Background: Biotin is currently a matter of concern for laboratories using biotin-streptavidin-based immunoassays. Biotin interferences have been reported for high-sensitive troponin T (hsTnT) and thyroid-stimulating hormone (TSH) assays. We aimed to evaluate the new generation of hsTnT and TSH electrochemiluminescent immunoassays announced to be less sensitive to biotin. Methods: Firstly, we assessed the analytical performances of new generation assays (imprecision, bias, total error, limit of quantification) and compared previous and new generation assays in the absence of biotin. Secondly, we challenged both generations of assays with samples spiked with seven different biotin levels. The efficiency of new generation assays was also compared to the streptavidin beads treatment. Results: New generation assays presented suitable analytical performances. Previous and new generations of hsTnT and TSH assays were commutable in the absence of biotin. In the presence of biotin, we confirmed that previous generation assays were affected by biotin concentration as low as 40.5 ng/mL and that new generation assays were not affected up to the announced tolerance threshold of 1200 ng/mL. After the streptavidin beads treatment, we observed a higher imprecision for both parameters and a constant 10% negative bias for TSH compared to new generation assays. Conclusions: New generation of electrochemiluminescent immunoassays appears as a reliable systematic solution to prevent biotin interference for hsTnT and TSH testing.
- 22 April 2020
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (12) , 2037-2045
Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing
Background: Biotin is currently a matter of concern for laboratories using biotin-streptavidin-based immunoassays. Biotin interferences have been reported for high-sensitive troponin T (hsTnT) and thyroid-stimulating hormone (TSH) assays. We aimed to evaluate the new generation of hsTnT and TSH electrochemiluminescent immunoassays announced to be less sensitive to biotin. Methods: Firstly, we assessed the analytical performances of new generation assays (imprecision, bias, total error, limit of quantification) and compared previous and new generation assays in the absence of biotin. Secondly, we challenged both generations of assays with samples spiked with seven different biotin levels. The efficiency of new generation assays was also compared to the streptavidin beads treatment. Results: New generation assays presented suitable analytical performances. Previous and new generations of hsTnT and TSH assays were commutable in the absence of biotin. In the presence of biotin, we confirmed that previous generation assays were affected by biotin concentration as low as 40.5 ng/mL and that new generation assays were not affected up to the announced tolerance threshold of 1200 ng/mL. After the streptavidin beads treatment, we observed a higher imprecision for both parameters and a constant 10% negative bias for TSH compared to new generation assays. Conclusions: New generation of electrochemiluminescent immunoassays appears as a reliable systematic solution to prevent biotin interference for hsTnT and TSH testing.
- Open Access
- 30 October 2019
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (3) , 408-415
Macro vitamin B12: an underestimated threat
Background: The correct identification of the macro-B12 interference (macroforms) is paramount to avoid potential erroneous clinical decisions. Our objectives were to determine whether immunoassays are affected by the presence of macro-B12 and to validate a polyethylene glycol (PEG) precipitation procedure to detect it. Methods: Sixty-two serum samples obtained from healthy volunteers were analyzed to determine recovery and reference intervals (RIs) following PEG precipitation. Thereafter, 50 serum samples with very high levels of B12 (>1476 pmol/L) were randomly selected to search for macro-B12 interferences. Serum samples obtained from healthy volunteers and related PEG aliquots were analyzed on a Cobas® immunoassay. Patients’ samples were analyzed on both Cobas® and Architect® immunoassays. Finally, samples suspected to contain macro-B12 were analyzed by size-exclusion chromatography (SEC) to confirm the presence of macro-B12. Results: Recovery and post-PEG RIs determined on a Cobas 8000® in healthy volunteers ranged from 68.3% to 108.4% and from 122.1 to 514.4 pmol/L, respectively. Fifteen samples (30%) were found to show macro-B12 while using the recovery criteria, and nine samples (18%) while using the post-PEG RI. The other immunoassay ran on the Architect i2000® was also affected by the presence of macro-B12. Size-exclusion chromatography studies confirmed the presence of macro-B12 (immunoglobulin-B12 complexes). Conclusions: The prevalence of macro-B12 in elevated B12 samples is high. We suggest to systematically screen for the presence of macro-B12 with PEG precipitation procedure in samples with elevated B12 levels to avoid potential misdiagnosis or harmful clinical consequences.
- 30 October 2019
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (3) , 408-415
Open AccessMacro vitamin B12: an underestimated threat
Background: The correct identification of the macro-B12 interference (macroforms) is paramount to avoid potential erroneous clinical decisions. Our objectives were to determine whether immunoassays are affected by the presence of macro-B12 and to validate a polyethylene glycol (PEG) precipitation procedure to detect it. Methods: Sixty-two serum samples obtained from healthy volunteers were analyzed to determine recovery and reference intervals (RIs) following PEG precipitation. Thereafter, 50 serum samples with very high levels of B12 (>1476 pmol/L) were randomly selected to search for macro-B12 interferences. Serum samples obtained from healthy volunteers and related PEG aliquots were analyzed on a Cobas® immunoassay. Patients’ samples were analyzed on both Cobas® and Architect® immunoassays. Finally, samples suspected to contain macro-B12 were analyzed by size-exclusion chromatography (SEC) to confirm the presence of macro-B12. Results: Recovery and post-PEG RIs determined on a Cobas 8000® in healthy volunteers ranged from 68.3% to 108.4% and from 122.1 to 514.4 pmol/L, respectively. Fifteen samples (30%) were found to show macro-B12 while using the recovery criteria, and nine samples (18%) while using the post-PEG RI. The other immunoassay ran on the Architect i2000® was also affected by the presence of macro-B12. Size-exclusion chromatography studies confirmed the presence of macro-B12 (immunoglobulin-B12 complexes). Conclusions: The prevalence of macro-B12 in elevated B12 samples is high. We suggest to systematically screen for the presence of macro-B12 with PEG precipitation procedure in samples with elevated B12 levels to avoid potential misdiagnosis or harmful clinical consequences.
- Open Access
- 28 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (9) , 1697-1701
Intentional acetylsalicylic acid acute intoxication and its clinical management
In the last decade, our knowledge about OTC drug intoxication has been expanded much further relative to previous years, though the absence of antidotes in some cases results in healthcare professionals using symptomatic treatment. This case report reminds the reader of the importance of clinical and toxicology laboratories in the management of acute salicylate intoxication in order to avoid hemodialysis.
- 28 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (9) , 1697-1701
Open AccessIntentional acetylsalicylic acid acute intoxication and its clinical management
In the last decade, our knowledge about OTC drug intoxication has been expanded much further relative to previous years, though the absence of antidotes in some cases results in healthcare professionals using symptomatic treatment. This case report reminds the reader of the importance of clinical and toxicology laboratories in the management of acute salicylate intoxication in order to avoid hemodialysis.